Zunsemetinib for COVID-19: real-time analysis

c19early.org

Zunsemetinib for COVID-19

1 study with 20 patients

Serious outcome risk

Zunsemetinib

Control

No significant improvements are seen in meta-analysis to date.

COVID-19 Zunsemetinib studies · November 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)0%

Mortality (1)0%

RCTs (1)0%

Late (1)0%

00.511.5+

← Zunsemetinib
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

Zunsemetinib (ATI-450) is an investigational, orally administered, small-molecule anti-inflammatory drug that inhibits the p38α→MK2 inflammatory signaling pathway, potentially reducing cytokine storm for COVID-19.


Jun 4 2025	Gan et al., NCT04481685	A Double-blind, Randomized, Controlled Trial of ATI-450 in Patients With Moderate-severe COVID-19
Jun 4 2025	no change in mortality (p=1) and 25% higher progression (p=1). RCT 20 hospitalized patients showing no significant difference in outcomes with ATI-450 (zunsemetinib).

Most accessed treatments

Antiviral effects

Vitamins & Minerals

Host endosomal entry / trafficking

Dual-action mAbs

RdRp

Nasal & Oral Sprays / Rinses

Analgesics

Antiandrogens

Host targets and pathways

Inflammatory and immune modulation

Mpro (Gen 1)

Oxidative stress and cytoprotection

Lifestyles

TMPRSS2

Spike neutralization

Replication inhibition (target unresolved)

COVID-19 mAbs

Pleiotropic modulation

Attachment / entry inhibition

Mpro (Gen 2)

H1RAs

Nutrients and microbiome support

Host mAbs

IL-6 / IL-6R blockade

Physical and extracorporeal interventions

Natural products and extracts

Symptom management

Unconfirmed antiviral rationale

Lifestyle, behaviors, and exposure prevention

Other complication management

Mpro / 3CLpro

Host pyrimidine synthesis

Direct viral inactivation

Endothelial / vascular protection

Direct respiratory tract treatments

Other antibodies, proteins, peptides, cells, and RNA therapies

Secondary infection and coinfection management

Zunsemetinib for COVID-19: real-time analysis